Inclusion Criteria:

          -  Biopsy proven locally recurrent adenocarcinoma of the prostate after the completion of
             definitive radiation therapy for initially diagnosed prostate cancer.

               -  Biopsy must be performed within 182 days of trial registration

               -  Biopsy should be a standard sextant biopsy AND either a targeted MR/ultrasound
                  guided biopsy or saturation biopsy or both.

          -  Initial cancer diagnosis that fits these specific criteria:

               -  Stages T1-T3a

               -  Nx or N0

               -  Mx or M0

          -  Eligible initial definitive radiotherapy modalities include:

          -  External beam radiotherapy, with photon or proton beam therapy

               -  Conventional or moderately hypofractionated radiotherapy

               -  Extremely hypofractionated external beam radiotherapy (Stereotactic body
                  radiation therapy)

          -  Definitive Brachytherapy:

               -  Low-dose rate

               -  High-dose rate

          -  Locally recurrent disease confined to the prostate +/- seminal vesicles and
             immediately adjacent tissue, as evaluated by the following:

               -  History/Physical examination

               -  Radiographically node negative disease (N0), as defined by CT or MR of pelvis +/-
                  abdomen within 6 months of registration.

               -  No evidence of bone metastases (M0) on bone scan within 6 months of registration.

               -  Fluciclovine-PET is encouraged, but not required

          -  Patients receiving ADT are eligible as long as they meet the other eligibility
             criteria. However, the duration of all ADT must be documented.

          -  Current ECOG Performance status Scale 0-2

          -  Current International Prostate Symptom Score (IPSS) < 20

          -  The patient must be medically suitable to receive general anesthesia.

          -  The patient must be able and willing to sign a study-specific written informed consent
             form before study entry.

        Exclusion Criteria:

          -  Preregistration GI or GU toxicity (for any reason) grade ≥ 3 as defined in CTCAE
             version 4.03. That is, grade ≥ 3 GU or GI toxicity after first course of radiotherapy

          -  Patients receiving any other investigational agents.

          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, severely symptomatic congestive heart failure, cardiac arrhythmia, recent
             myocardial infarction in last 6 months, or psychiatric illness/social situations that
             could limit compliance with study requirements.

          -  Patients who have received chemotherapy or immunotherapy within one month prior to
             study enrollment, other than ADT